Bausch & Lomb could go public as early as the end of this year, the Wall Street Journal reported, citing people familiar with the company's thinking.
The eye-care company's Chief Executive Brent Saunders told Reuters last October that he was setting sights on an IPO for the company "in the next couple of years."
Bausch & Lomb and its private equity owner Warburg Pincus declined to comment.
Previously traded on the New York Stock Exchange, the Rochester, New York-based company was acquired for $4.5 billion by Warburg Pincus in late 2007 after falling out of Wall Street's favor because of product recalls, big charges and restatements of earnings.
Bausch & Lomb agreed to buy Ista Pharmaceuticals Inc in March for about $500 million in cash to broaden its portfolio of eye health products.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
